Johns Hopkins spinout AsclepiX Therapeutics raised $5 million in new funding that will assist in development of new treatment for eye diseases that are leading causes of blindness in adults.
{iframe}https://technical.ly/baltimore/2018/11/15/baltimore-based-asclepix-therapeutics-raises-5m/?utm_campaign=Baltimore%20Editorial%20Email&utm_source=hs_email&utm_medium=email&utm_content=67586709&_hsenc=p2ANqtz-8uWiPe30TF0ERQl7R65NI00RSiFGlyCi7aGozDHxNJWKI6k8mSfym2MlxTwzQNhvZunwKdbF1BANwxLju_xqV7pdZGLw&_hsmi=67586709{/iframe}